Drug patenting in India: looking back and looking forward

Shadlen, Kenneth C. ORCID: 0000-0003-4010-4835 and Sampat, Bhaven N. (2015) Drug patenting in India: looking back and looking forward. South Asia @ LSE (09 Nov 2015). Blog Entry.

Text (southasia_2015-11-9-drug-patenting-in-india) - Published Version Download (906kB)

• Author
• https://blogs.lse.ac.uk/southasia/2015/1...

Abstract

It has now been 20 years since the TRIPS Agreement, which established minimum standards for intellectual property (IP) regulation, came into force. Its implementation in India has been controversial, and in particular Section 3(d), a provision designed to restrict the grant of “secondary” patents, has been pinpointed as making it difficult to obtain pharmaceutical patents. Ken Shadlen and Bhaven Sampat suggest that paying so much attention to 3(d) may be misplaced. They argue that another, more fundamental, aspect of TRIPS implementation in India, the timing of the country’s adoption of pharmaceutical patents, is more important than 3(d) for understanding the current patenting landscape. And because the effects of timing are transitional, in the future it may be less difficult to obtain patents in India than is widely thought.

Item Type:	Online resource (Blog Entry)
Official URL:	http://blogs.lse.ac.uk/southasia/
Additional Information:	© 2015 The Authors
Divisions:	International Development
Subjects:	H Social Sciences > HB Economic Theory J Political Science > JC Political theory J Political Science > JQ Political institutions Asia, Africa, Australia, Pacific R Medicine > RM Therapeutics. Pharmacology R Medicine > RS Pharmacy and materia medica
Date Deposited:	02 May 2017 08:04
Last Modified:	11 Dec 2024 20:07
URI:	http://eprints.lse.ac.uk/id/eprint/74870

Actions (login required)

View Item